{"id":17078,"date":"2020-02-21T07:12:41","date_gmt":"2020-02-21T07:12:41","guid":{"rendered":"https:\/\/celonpharma.com\/?p=17078"},"modified":"2022-10-19T14:45:44","modified_gmt":"2022-10-19T14:45:44","slug":"baap","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/baap\/","title":{"rendered":"BAAP"},"content":{"rendered":"

\"\"<\/p>\n

Development of an innovative platform for the production of bispecific constructions based on Phage Display technique and the preclinical and clinical development of an innovative bispecific drug candidate for the treatment of inflammatory diseases<\/span><\/h2>\n

<\/p>\n

Funding Agreement No.: POIR.01.02.00-00-0081\/18-00 under Measure 1.2: \u201cSectoral R&D programmes\u201d
\nDate of the contract conclusion: 20\/03\/2019<\/p>\n

The aim of the project is to develop an innovative platform for the screening, design and production of bispecific biotechnological therapeutic agents in the treatment of inflammatory diseases, using the Phage Display technique and an innovative expression systems. Nowadays, bispecific constructs represent one of the most innovative trends in the development of the treatment. Such an approach enables the design of molecules capable of simultaneously inhibiting\/modulating two molecular targets, thus allowing for synergistic action of both therapeutic elements and increasing the effectiveness of treatment and patient safety.<\/p>\n

The project will result in the development and evaluation during clinical research of an innovative biotechnology product used in the treatment of inflammatory diseases such as rheumatoid arthritis, psoriasis or inflammatory bowel disease including Crohn’s disease and ulcerative colitis. Such diseases constitute an enormous social problem which frequently affects low income people. Implementation of the project results will considerably decrease the price of the latest generation of drugs, thus making them more available to patients, which will translate into lower socioeconomic costs of the problem.<\/p>\n


\nTotal value of the BAAP project:\u00a0PLN 39,815,485.00
\n<\/strong>Total value of funding:\u00a0PLN 24,650,532.50<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Development of an innovative platform for the production of bispecific constructions based on Phage Display technique and the preclinical and clinical development of an innovative bispecific drug candidate for the treatment of inflammatory diseases<\/p>\n","protected":false},"author":20,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[97],"tags":[],"class_list":["post-17078","post","type-post","status-publish","format-standard","hentry","category-ue-co-financed-projects-ended"],"acf":[],"yoast_head":"\nBAAP - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/baap\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BAAP - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"Development of an innovative platform for the production of bispecific constructions based on Phage Display technique and the preclinical and clinical development of an innovative bispecific drug candidate for the treatment of inflammatory diseases\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/baap\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-21T07:12:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-19T14:45:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/baap\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/baap\\\/\"},\"author\":{\"name\":\"Ma\u0142gorzata Siewierska\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"headline\":\"BAAP\",\"datePublished\":\"2020-02-21T07:12:41+00:00\",\"dateModified\":\"2022-10-19T14:45:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/baap\\\/\"},\"wordCount\":240,\"image\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/baap\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/1178-106-max-1024x92.png\",\"articleSection\":[\"UE - co-financed projects ended\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/baap\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/baap\\\/\",\"name\":\"BAAP - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/baap\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/baap\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/1178-106-max-1024x92.png\",\"datePublished\":\"2020-02-21T07:12:41+00:00\",\"dateModified\":\"2022-10-19T14:45:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/baap\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/baap\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/baap\\\/#primaryimage\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/1178-106-max-1024x92.png\",\"contentUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/1178-106-max-1024x92.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/baap\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BAAP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\",\"name\":\"Ma\u0142gorzata Siewierska\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BAAP - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/baap\/","og_locale":"en_US","og_type":"article","og_title":"BAAP - Celon Pharma","og_description":"Development of an innovative platform for the production of bispecific constructions based on Phage Display technique and the preclinical and clinical development of an innovative bispecific drug candidate for the treatment of inflammatory diseases","og_url":"https:\/\/celonpharma.com\/en\/baap\/","og_site_name":"Celon Pharma","article_published_time":"2020-02-21T07:12:41+00:00","article_modified_time":"2022-10-19T14:45:44+00:00","og_image":[{"url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png","type":"","width":"","height":""}],"author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/baap\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/baap\/"},"author":{"name":"Ma\u0142gorzata Siewierska","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"headline":"BAAP","datePublished":"2020-02-21T07:12:41+00:00","dateModified":"2022-10-19T14:45:44+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/baap\/"},"wordCount":240,"image":{"@id":"https:\/\/celonpharma.com\/en\/baap\/#primaryimage"},"thumbnailUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png","articleSection":["UE - co-financed projects ended"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/baap\/","url":"https:\/\/celonpharma.com\/en\/baap\/","name":"BAAP - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/celonpharma.com\/en\/baap\/#primaryimage"},"image":{"@id":"https:\/\/celonpharma.com\/en\/baap\/#primaryimage"},"thumbnailUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png","datePublished":"2020-02-21T07:12:41+00:00","dateModified":"2022-10-19T14:45:44+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/baap\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/baap\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/celonpharma.com\/en\/baap\/#primaryimage","url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png","contentUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png"},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/baap\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"BAAP"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c","name":"Ma\u0142gorzata Siewierska"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/17078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=17078"}],"version-history":[{"count":2,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/17078\/revisions"}],"predecessor-version":[{"id":26421,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/17078\/revisions\/26421"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=17078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=17078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=17078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}